ARIAD Appoints Fritz Casselman, Former SmithKline Executive, to New Position of Chief Business Officer and Senior Vice President.Business & Health Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2001 ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced the appointment of Mr. Fritz Casselman to the newly created position of chief business officer and senior vice president. Mr. Casselman currently is senior vice president, strategy and corporate development at Avant Immunotherapeutics, Inc. and most recently was director of worldwide business development at SmithKline Beecham, plc. At ARIAD, Mr. Casselman will be responsible for business development, licensing and commercial operations and will be a member of the Company's executive committee. Previously, Mr. Casselman was vice president and general counsel at Cambridge Biotech Corporation, a partner at Bromberg, Sunstein & Casselman, a high-technology law firm in Boston, and chief counsel of the Massachusetts Labor Relations Commission. Mr. Casselman earned a J.D. from Boston University Boston University, at Boston, Mass.; coeducational; founded 1839, chartered 1869, first baccalaureate granted 1871. It is composed of 16 schools and colleges. Law School and a B.A. from the University of Wisconsin (Madison). "Mr. Casselman's wealth of experience in structuring and negotiating commercial partnerships makes him ideally suited to lead our business activities. Fritz brings almost twenty years TWENTY YEARS. The lapse of twenty years raises a presumption of certain facts, and after such a time, the party against whom the presumption has been raised, will be required to prove a negative to establish his rights. 2. of pharmaceutical and biotechnology expertise to our executive team," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. Mr. Casselman added, "Given the untapped value of ARIAD's technologies and products, completing a series of licenses and partnerships should be readily achievable. My highest priority is to further monetize these assets this year through revenue-generating transactions." ARIAD Pharmaceuticals, Inc. (www.ariad.com) is a leader in the discovery and development of gene therapy, cell therapy, stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs and protein therapy products featuring dose-dependent regulation by small-molecule drugs, as well as small-molecule inhibitors of signal transduction Signal transduction The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells. . Some of the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, which include, but are not limited to, the risks and uncertainties regarding the Company's success in entering into commercial transactions that are of value to the Company, as well as risks and uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc economic conditions, markets, products, clinical and preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. , intellectual property, services and prices, key employees, future capital needs, dependence on our collaborators and other factors under the heading "Cautionary Statement Regarding Forward-Looking Statements" in ARIAD's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 1999 filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion